1
|
Li ZC, Li M, Xiao LX, Zheng X, Li R, Dong SJ, Wang Y, Wen HY, Ruan KL, Cheng KG, Chen M, Tan YH. 6-O-angeloylplenolin inhibits osteoclastogenesis in vitro via suppressing c-Src/NF-κB/NFATc1 pathways and ameliorates bone resorption in collagen-induced arthritis mouse model. Biochem Pharmacol 2024; 224:116230. [PMID: 38643905 DOI: 10.1016/j.bcp.2024.116230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 04/02/2024] [Accepted: 04/19/2024] [Indexed: 04/23/2024]
Abstract
One of the effective therapeutic strategies to treat rheumatoid arthritis (RA)-related bone resorption is to target excessive activation of osteoclasts. We discovered that 6-O-angeloylplenolin (6-OAP), a pseudoguaianolide from Euphorbia thymifolia Linn widely used for the treatment of RA in traditional Chinese medicine, could inhibit RANKL-induced osteoclastogenesis and bone resorption in both RAW264.7 cells and BMMs from 1 μM and protect a collagen-induced arthritis (CIA) mouse model from bone destruction in vivo. The severity of arthritis and bone erosion observed in paw joints and the femurs of the CIA model were attenuated by 6-OAP administered at both dosages (1 or 5 mg/kg, i.g.). BMD, Tb.N and BV/TV were also improved by 6-OAP treatment. Histological analysis and TRAP staining of femurs further confirmed the protective effects of 6-OAP on bone erosion, which is mainly due to reduced osteoclasts. Molecular docking indicated that c-Src might be a target of 6-OAP and phosphorylation of c-Src was suppressed by 6-OAP treatment. CETSA and SPR assay further confirmed the potential interaction between 6-OAP and c-Src. Three signaling molecules downstream of c-Src that are vital to the differentiation and function of osteoclasts, NF-κB, c-Fos and NFATc1, were also suppressed by 6-OAP in vitro. In summary, the results demonstrated that the function of c-Src was disrupted by 6-OAP, which led to the suppression of downstream signaling vital to osteoclast differentiation and function. In conclusion, 6-OAP has the potential to be further developed for the treatment of RA-related bone erosion.
Collapse
Affiliation(s)
- Zhi-Chao Li
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Min Li
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Ling-Xiang Xiao
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Xi Zheng
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Rong Li
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Shi-Jia Dong
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Yue Wang
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Hong-Yu Wen
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Kun-Lin Ruan
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China
| | - Ke-Guang Cheng
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China.
| | - Ming Chen
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China.
| | - Yan-Hui Tan
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, Guangxi, PR China.
| |
Collapse
|
2
|
Qiu JM, Zeng FF, Cheng C, Wen HY, Huang SQ, Liu D, Qi JL, Yin P, Zhou MG, Xu Y, Liu ZP, Mei QS, Xiao H, Xiang Z, Liang XF. [Disease burden of acute viral hepatitis in Guangdong Province, 1990-2019]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:365-372. [PMID: 38514313 DOI: 10.3760/cma.j.cn112338-20230830-00108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To examine the burden and trends of acute viral hepatitis in Guangdong Province from 1990 to 2019, and provide reference evidences for hepatitis prevention and control in the province. Methods: Data on acute viral hepatitis (hepatitis A, B, C, and E) in Guangdong from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019 database. The incidence, prevalence, mortality, and disability-adjusted life years (DALY) data were analyzed by age and gender, and the estimated annual percentage change (EAPC) was calculated to describe the changing trends in disease burden. Results: From 1999 to 2019, the standardized incidence, prevalence, mortality, and DALY of acute viral hepatitis in Guangdong were higher than the national averages. In 2019, 51.43% (2 245 087/4 365 221) of acute viral hepatitis cases in Guangdong Province were mainly attributed to hepatitis B, and 77.18% (106/138) of deaths were due to acute hepatitis B. In different age groups, except for acute hepatitis B, which was more common in adults, the incidence rates of other types of viral hepatitis such as hepatitis A, B, and E showed an overall decreasing trend with age. The mortality rates of different types of acute viral hepatitis, except for the <5 age group, increased with age. The overall incidence and mortality rates of acute viral hepatitis were higher in men than in women. Conclusions: The overall burden of acute viral hepatitis in Guangdong declined in 2019, but remained higher than the national level. Further efforts are needed to strengthen hepatitis prevention and screening in different population in Guangdong Province, especially in children and the elderly.
Collapse
Affiliation(s)
- J M Qiu
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| | - F F Zeng
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| | - C Cheng
- Department of Medical Affairs, the First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital), Guangzhou 510630, China
| | - H Y Wen
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| | - S Q Huang
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| | - D Liu
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| | - J L Qi
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - P Yin
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - M G Zhou
- National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Y Xu
- Chronic Disease Prevention and Control Hospital of Bao'an District, Shenzhen 518020, China
| | - Z P Liu
- Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 511436, China
| | - Q S Mei
- Department of Medical Biochemistry and Molecular Biology, School of Basic Medical and Public Health, Jinan University, Guangzhou 510632, China
| | - H Xiao
- School of Life Science and Technology/Research Institute of Pathogenic Microorganisms, Jinan University, Guangzhou 510632,China
| | - Z Xiang
- Department of Microbiology and Immunology, School of Basic Medicine and Public Health, Jinan University, Guangzhou 510632, China
| | - X F Liang
- Department of Preventive Medicine, School of Basic Medicine and Public Health, Jinan University/Disease Control and Prevention Institute of Jinan University/Kangtai Biological Vaccine Industry Research Institute, Jinan University, Guangzhou 510632, China
| |
Collapse
|
3
|
Koleoso OA, Ehrich F, Grabensetter A, Wen HY, Zhang Z, Braunstein LZ, Xu AJ, McCormick B, Morrow M, Powell SN, Khan AJ. Oncotype Recurrence Score (RS) at the Extremes of Tumor Size: Which Drives Clinical Outcomes? Int J Radiat Oncol Biol Phys 2023; 117:e188. [PMID: 37784818 DOI: 10.1016/j.ijrobp.2023.06.1048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Tumor size is an established and independent risk factor for local-regional recurrence (LRR) and distant recurrence (DM). More recently, the recurrence score calculated from a 21-gene expression assay (Oncotype DXTM, Exact Sciences) has also been correlated with LRR and DM. We sought to determine the impact of the interaction between tumor size and Oncotype RS, particularly when the variables are in discrepancy with each other. More specifically, we evaluated clinical outcomes in patients with small tumors (≤1 cm) and high RS (≥26) and, separately, in patients with large tumors (>5 cm) with low RS. MATERIALS/METHODS Between 2008 and 2020, 310 patients were identified retrospectively as having been treated for early-stage, hormone-receptor positive, Her2-negative breast cancers with tumor size ≤1 cm that were node-negative and had RS ≥ 26 at our institution. In addition, 64 patients were identified with tumor size >5 cm and RS < 26 (irrespective of nodal status). Locoregional recurrence rates (LRR) and invasive recurrence rates (composite of LRR and distant recurrence) were estimated using the Kaplan-Meier method. RESULTS Patient characteristics are shown in Table 1. In the group of patients with small tumors and high RS, the 5- and 10-year invasive recurrence rates with 95% CI were 8% (4.2-12) and 17% (8.2-26). The 5- and 10-year locoregional recurrence rates with 95% CI were 5.8% (2.7-8.8) and 15% (6.2-23). In the group of patients with large tumors and low RS, 10-year rates could not be estimated with the available data. The 5- and 8-year invasive recurrence rates with 95% CI were 3.2% (0-7.5) and 3.2% (0-7.5). The 5- and 8-year locoregional recurrence rates with 95% CI were 1.6% (0-4.7) and 1.6% (0-4.7). CONCLUSION Our findings suggest that patients with small tumors and high RS are at a higher risk for LRR compared to the average ≤1 cm node-negative breast cancer based on published data on the effect of tumor size on LRR and DM. Similarly, tumors larger than 5 cm with low RS appear to behave indolently and in a manner consistent with more favorable risk (despite their large size). These findings may have important implications for the tailoring of local-regional treatment strategies.
Collapse
Affiliation(s)
- O A Koleoso
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - F Ehrich
- Memorial Sloan Kettering Cancer center, New York, NY
| | | | - H Y Wen
- Memorial Sloan Kettering Cancer center, New York, NY; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Z Zhang
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Z Braunstein
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - A J Xu
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - B McCormick
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Morrow
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
| | - S N Powell
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - A J Khan
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
4
|
Zheng JL, Wen HY, Zhang B, Gong JH, Teng Y, Li ZY. Development of Integrated Device of Trace Bloodstains Imaging and Age Analysis. Fa Yi Xue Za Zhi 2019; 35:230-233. [PMID: 31135120 DOI: 10.12116/j.issn.1004-5619.2019.02.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Indexed: 11/30/2022]
Abstract
Abstract Objective To develop a device of trace bloodstains imaging and age analysis, so as to provide a non-destructive, simple and objective method for age estimation of bloodstains at the crime scene. Methods Based on the principle of digital imaging and color pattern analysis, the mobile terminal of the device was used to collect images of bloodstains of different ages. The time-dependent pattern of 6 parameters (R, G, B, C, Y, M) reflecting the changes of color of images of different ages was obtained by computer image analysis. A multiparameter comprehensive inference equation of bloodstains age was established and embedded into the device software to realize the intelligent inference of the bloodstains age. Then the capability and reliability of the device was verified. Results This integrated device of bloodstains imaging and age analysis could quickly collect bloodstains at the crime scene and automatically analyze and infer the age of bloodstains combined with related intelligence software. In the blind test, the detection accuracy of this device was 95% in both natural light airtight group and dark airtight group, and 80% in the natural light ventilation group. Conclusion The integrated device of trace bloodstains imaging and age analysis can be used in a simple manner, which provides a new objective method for bloodstains age estimation.
Collapse
Affiliation(s)
- J L Zheng
- Department of Forensic Medicine, Criminal Investigation Police University of China, Shenyang 110035, China
| | - H Y Wen
- Network Information Center, Criminal Investigation Police University of China, Shenyang 110035, China
| | - B Zhang
- Forensic Department of Criminal Technology Center, CID of Shanghai Public Security Bureau, Shanghai 200000, China
| | - J H Gong
- Department of Criminal Technology, Guizhou Police College, Guiyang 550005, China
| | - Y Teng
- Department of Forensic Medicine, Criminal Investigation Police University of China, Shenyang 110035, China
| | - Z Y Li
- Department of Forensic Medicine, Criminal Investigation Police University of China, Shenyang 110035, China.,Raohe Public Security Bureau, Shuangyashan 155700, Heilongjiang Province, China
| |
Collapse
|
5
|
Beca F, Yang SR, Gruber JG, Barry-Holson K, West R, Wen HY, Allison KH. Abstract P2-07-07: Development of a machine learning-based classifier for Oncotype DX® category prediction in a population of lymph node positive breast carcinoma patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION: Oncotype DX® (ODX) Assay is a valuable prognostic and predictive tool in ER+, Her2- invasive breast cancer (IBC). Initially tested and validated in lymph node (LN) negative patients, the indications of this test have been expanded to include patients with limited LN-positive disease. Several prediction systems have been developed to predict the ODX Recurrence Score (RS) with substantial performance in predicting a high vs low RS score but with low performance when predicting the 3 classes that compose the standard ODX. Additionally, many of these prediction systems have not been developed and/or tested for a population of LN+ patients.
OBJECTIVES: The primary objective of this study was to evaluate the performance of several previously published ODX RS predictive systems in a population of LN+ patients. Furthermore, we developed a machine-learning based classification system to accurately predict the ODX 3 category RS for this specific population.
METHODS: We conducted a retrospective search of Stanford's pathology database for all patients with LN+ IBC diagnosed between January 2013 and December 2017 with an ODX RS available. A total of 119 patients were identified for inclusion in this cohort. Our multivariate pathologic feature-based discriminatory model aimed to classify each case as belonging to the low, intermediate or high ODX RS category. We performed model validation by the 10-fold cross validation (10F-CV) method. The model's performance was assessed by comparing simple accuracy, balanced accuracy, F1 score (harmonic average of the precision and recall) and several concordance classification metrics.
RESULTS: Of the evaluated methods, Magee equations performed well in this population of LN+ patients with the modified Magee equation 2 displaying the best accuracy (70.9%) which was surprisingly better than originally reported (55.8%, in Klein et al. Mod Path. 2013). After an initial screen of methods and tuning of the best performing model, our model achieved an overall accuracy of 78.1% on 10F-CV with a 79.1 % balanced accuracy and no two-step discordances. This corresponded to an increase of weighted Cohen's kappa of 30% versus the best performing Magee equation in this cohort and an increase of 103% versus the modified Magee 1 equation (which uses the same features as our model except for tumor grade).
DISCUSSION: Classifiers aimed at providing an alternative to Oncotype DX testing are available and perform consistently across datasets. We are currently validating our approach in a population of 1000 LN-negative patients from the MSKCC and the SEER database. Due to the substantial performance of our machine learning-based classifier based on standard reported pathologic features, our model may be considered an alternative to the ODX standard testing or a screening method for ODX testing, especially for cases with where the cost and availability of the ODX test are a concern.
Citation Format: Beca F, Yang S-R, Gruber JG, Barry-Holson K, West R, Wen HY, Allison KH. Development of a machine learning-based classifier for Oncotype DX® category prediction in a population of lymph node positive breast carcinoma patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-07.
Collapse
Affiliation(s)
- F Beca
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - S-R Yang
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - JG Gruber
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - K Barry-Holson
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - R West
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - HY Wen
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| | - KH Allison
- Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York City, NY
| |
Collapse
|
6
|
Lee JY, Bi R, Pareja F, Geyer FC, Brown D, Wen HY, Norton L, Hicks J, Weigelt B, Reis-Filho JS. Abstract P2-01-02: Whole exome sequencing analysis of the progression from ductal carcinoma in situ to invasive ductal carcinoma. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Ductal carcinoma in situ (DCIS) is a bona fide non-obligate precursor of invasive carcinoma. Single cell sequencing studies have revealed intra-lesion genetic heterogeneity in DCIS and shown that progression to invasive ductal carcinoma (IDC) may occur through different mechanisms, including the selection of a subpopulation of tumor cells, acquisition of new genetic alterations or multi-clonal invasion. Here, we sought to investigate the genetic heterogeneity of DCIS, and to document further the clonal selection process accompanying progression to IDC.
Materials and methods: Synchronous DCIS (n=16) and IDC (n=15) samples from 14 patients were microdissected separately, and DNA samples of tumor and matched normal tissues were subjected to whole-exome sequencing (WES; n=27) or massively parallel targeted sequencing of all coding regions of ≥410 cancer-related genes (n=4). Somatic genetic alterations and mutational signatures were identified using state-of-the-art bioinformatics algorithms. PyClone was employed to define the clonal architecture of each DCIS and IDC and infer the clonal shifts accompanying progression from DCIS to IDC.
Results: DCIS were found to harbor recurrent somatic mutations affecting PIK3CA (50%), GATA3 (44%), TP53 (38%), CBFB (19%), PTEN (13%), and AKT1 (13%), which are genes known to be significantly mutated in invasive breast cancers. Despite the genomic similarities between matched DCIS and IDCs, NOTCH2 and MYC were found to be amplified solely in the IDC component of two cases, and PPM1D amplification was restricted to the DCIS component of another case. The mutational signature ascribed to aging (i.e. signature 1) was the predominant mutational signature in the DCIS and IDCs analyzed. PyClone analysis revealed that all synchronous DCIS and IDC studied here were clonally related and confirmed the previous observation that DCIS displays intra-lesion genetic heterogeneity. Evidence of clonal selection in the progression from DCIS to IDC was observed in three cases, whereby a minor DCIS subclone likely constituted the substrate for the development of IDC. In one of these cases, from a patient with a BRCA1 germline pathogenic mutation, we observed a shift from the mutational signature associated with defective homologous recombination DNA repair (i.e. signature 3) to the APOBEC-related mutational signatures (i.e. signatures 2 and 13) in the progression from DCIS to IDC.
Conclusion: Intra-lesion genetic heterogeneity is a common feature in DCIS synchronously diagnosed with IDC. Our findings corroborate the notion that DCIS is a direct non-obligate precursor of IDC, and that clonal selection in the progression of DCIS to IDC may be present in a subset of cases, but is unlikely to constitute the most frequent mechanism of progression.
Citation Format: Lee JY, Bi R, Pareja F, Geyer FC, Brown D, Wen HY, Norton L, Hicks J, Weigelt B, Reis-Filho JS. Whole exome sequencing analysis of the progression from ductal carcinoma in situ to invasive ductal carcinoma [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-01-02.
Collapse
Affiliation(s)
- JY Lee
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - R Bi
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - F Pareja
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - FC Geyer
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - D Brown
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - HY Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - J Hicks
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA
| |
Collapse
|
7
|
Da Cruz Paula A, Brown D, Geyer FC, Smith E, Pareja F, Papanastasiou AD, Fusco N, Marchio C, Brogi E, Wen HY, Vincent-Salomon A, Norton L, Weigelt B, Reis-Filho JS. Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Metaplastic breast carcinomas (MBCs) and uterine carcinosarcomas (UCSs) are histologically similar, being often characterized by an admixture of adenocarcinoma areas with areas displaying sarcomatoid differentiation. We sought to investigate whether their histologic similarities would be paralleled by similar patterns of genetic alterations, and to determine whether the different histologic components of MBCs and UCSs would be clonally related.
Methods: Whole exome sequencing (WES) data from 35 MBCs previously analyzed by our group and 57 UCSs from The Cancer Genome Atlas (TCGA) study were reanalyzed. Somatic single nucleotide variants were detected with MuTect and indels with Strelka, Varscan2, Scalpel and Lancet. Copy number alterations were inferred using FACETS and functional annotation of the non-synonymous somatic mutations, amplifications or homozygous deletions was performed. We further microdissected the histologically distinct components of 11 MBCs and six UCSs and subjected each component to WES. Clonal decomposition was performed using PyClone.
Results: The most frequent somatic mutations identified in MBCs were TP53 (69%), PIK3CA (29%), FAT3 (26%) and PTEN (14%), whereas the most frequently mutated genes in UCSs were TP53 (84%), FBXW7 (35%), PIK3CA (29%), PTEN (15%) and PPP2R1A (15%). MBCs displayed a significantly higher frequency of mutations targeting FAT3 (26% vs 4%, P<0.01), FAT1 (11% vs 0%, P<0.05) and CHERP (11% vs 0%, P<0.05) than UCSs. UCSs more frequently harbored mutations affecting FBXW7 (35% vs 0%; P<0.01) and PPP2R1A (15% vs 0%, P<0.05) than MBCs. MBCs and UCSs displayed similar copy number alteration profiles, with frequent gains/ amplification of 8q, 3q and 1q, and losses of 8p. Pathway analysis based on the genes targeted by somatic genetic alterations revealed that both MBCs and UCSs were underpinned by genetic alterations resulting in activation of similar pathways, including PI3K, p53, Wnt and Notch signaling. Analysis of the separate components of MBCs and UCSs revealed that the histologically distinct components of MBCs and UCSs are clonally-related, with a median of 71% (range 26%-93%) and 78% (range 30%-93%) of somatic mutations being shared by the distinct components in MBCs and UCSs, respectively. In MBCs, clonal TP53, NOTCH3, KMT2D, FAT4 and PIK3CA mutations and several copy number alterations were shared by the histologically distinct components. Mutations private to each of the histologically distinct components included PIK3R1, CHERP and MAPK14 mutations. The carcinomatous and sarcomatous components of UCSs shared clonal TP53, PIK3CA, CDKN2A, ITGB7 and FGFR2 mutations. Private KMT2B mutations were identified in the UCS carcinomatous components. PyClone analysis revealed that the clonally-related histologically distinct components of each case harbored intra-component genetic heterogeneity coupled with parallel evolution.
Conclusions: Our findings support the contention that UCSs constitute the uterine counterpart of MBCs due to their similar histology and patterns of genetic alterations affecting the same signaling pathways (i.e. TP53, PI3K, Wnt and Notch). In each MBC and UCS analyzed here, the histologically distinct components were found to be clonally related.
Citation Format: Da Cruz Paula A, Brown D, Geyer FC, Smith E, Pareja F, Papanastasiou AD, Fusco N, Marchio C, Brogi E, Wen HY, Vincent-Salomon A, Norton L, Weigelt B, Reis-Filho JS. Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-02.
Collapse
Affiliation(s)
- A Da Cruz Paula
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - D Brown
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - FC Geyer
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - E Smith
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - F Pareja
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - AD Papanastasiou
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - N Fusco
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - C Marchio
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - E Brogi
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - HY Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - A Vincent-Salomon
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, New York, NY; FPO-IRCCS Candiolo Cancer Institute, University of Turin, Turin, Italy; Institute Curie, Paris, France
| |
Collapse
|
8
|
Kumar R, Pei X, Selenica P, Wen HY, Powell S, Robson M, Riaz N, Reis-Filho JS, Weigelt B, Mandelker D. Abstract P4-04-01: The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-04-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Checkpoint kinase 2 (CHEK2) is a tumor suppressor gene, which regulates cell cycle in response to DNA damage response. Selected CHEK2 germline mutations have been shown to confer an increased risk of breast cancer development. Multiple founder mutations in CHEK2 have been identified, and meta analyses have shown that CHEK2 truncating variants confer a higher breast cancer risk than missense variants. Here, we assessed the phenotype and repertoire of genetic alterations of breast cancers from 33 patients with CHEK2 pathogenic germline variants.
Materials and methods: We performed targeted capture massively parallel sequencing (≥410 genes) of tumor and normal samples from 13 patients with CHEK2 pathogenic germline variants, and retrieved whole exome sequencing (WES) data (BAM files) of tumor and normal samples from 20 patients with CHEK2 germline pathogenic variants included in the TCGA breast cancer study. In addition, we retrieved WES data of BRCA1, BRCA2 and ATM associated breast cancers from TCGA and Weigelt et al. (JNCI 2018). Somatic mutations, copy number alterations, mutational signatures and large-scale transitions (LSTs) were defined using state-of-the-art bioinformatics algorithms.
Results: Of the 33 CHEK2-associated breast cancers included in this study, 21 had missense and 12 had loss-of-function (LoF) germline mutations, and 81% were ER-positive and 12% HER2-positive. CHEK2-associated breast cancers statistically significantly less frequently displayed an ER-negative/HER2-negative phenotype (0%) than BRCA1- (80%) or BRCA2-associated (33%) breast cancers (BRCA1, p<0.0001 for both comparisons), but were similar to ATM-associated breast cancers. Biallelic inactivation of CHEK2 through loss of heterozygosity (LOH) of the wild-type allele was present in 17 of 33 samples (52%). LOH of the CHEK2 wild-type allele was significantly more frequent in tumors with LOF mutations than in those with missense mutations (78% vs 36%, respectively; p=0.0394). PIK3CA (36%) and GATA3 (33%) were the two most recurrently mutated genes in these samples. TP53 somatic mutations were detected in five cases, four of which harbored missense CHEK2 germline mutations. Unlike BRCA1- and BRCA2-associated breast cancers, but akin to ATM-associated breast cancers, CHEK2-associated breast cancers lacked the mutational signature associated with homologous recombination (HR) DNA repair defects (i.e. signature 3) and only five cases displayed high LST scores.
Conclusion:CHEK2-associated breast cancers are phenotypically and genetically distinct from BRCA1- and BRCA2-associated breast cancers, but similar to ATM-associated breast cancers. Akin to ATM-associated breast cancers, CHEK2-associated breast cancers are preferentially ER-positive, lack genomics features consistent with defective HR, and have a repertoire of somatic genetic alterations similar to those of non-BRCA1/2 ER-positive breast cancers. Our results suggest that either CHEK2 germline mutations contribute to an increased risk of breast cancer independently of the HR DNA repair defects or that the mutational signatures caused by CHEK2 pathogenic germline mutations differ from those caused by pathogenic germline mutations affecting bona fide HR-related genes (e.g. BRCA1, BRCA2 and PALB2).
Citation Format: Kumar R, Pei X, Selenica P, Wen HY, Powell S, Robson M, Riaz N, Reis-Filho JS, Weigelt B, Mandelker D. The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-04-01.
Collapse
Affiliation(s)
- R Kumar
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - X Pei
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - P Selenica
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - HY Wen
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Powell
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - N Riaz
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Mandelker
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
9
|
Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen HC, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Lozada J, Macedo GS, Muenst S, Terracciano LM, Jungbluth A, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha E, Chandarlapatty S, Weigelt B, Reis-Filho JS. Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd4-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:Adenomyoepithelioma (AME) of the breast is a rare biphasic tumor, characterized by epithelial and myoepithelial differentiation. Although AMEs have an indolent clinical course, a subset may progress to carcinoma and metastasize. We sought to define the mutational landscape of AMEs and investigate the functional impact of recurrent pathogenic mutations identified in these tumors.
Methods: Thirty-one AMEs were subjected to whole-exome sequencing (WES, n=8) or massively parallel sequencing targeting all coding regions of 410 key cancer genes and intronic and regulatory regions of selected genes (n=23). Somatic genetic alterations were defined using state-of-the-art bioinformatics algorithms. In an additional set of 12 AMEs, Sanger sequencing analysis of HRAS, PIK3CA and AKT1 was performed. Non-tumorigenic estrogen receptor (ER)-negative mammary epithelial cells (i.e. MCF10A, MCF10A with a PIK3CA H1047R mutation knock-in and MCF12A) were utilized for functional studies using both conventional monolayer and three-dimensional (3D) culture assays.
Results: 27 (63%) and 16 (37%) AMEs were ER-positive and ER-negative, respectively. ER-negativity was significantly associated with histologic features predictive of a more aggressive behavior, with a higher number of mutations and copy number alterations, and with a distinct mutational profile as compared to ER-positive AMEs. Of the 27 ER-positive AMEs, 12 cases (44%) harbored PIK3CA hotspot mutations, and 5 PIK3CA wild-type cases displayed E17K AKT1 hotspot mutations. By contrast, of the 16 ER-negative AMEs, 9 (56%), 9 (56%) and 3 (19%) harbored HRAS, PIK3CA (mostly E545K and H1047R hotspots) and PIK3R1 mutations, respectively. Strikingly, all HRAS mutations were restricted to ER-negative AMEs, affected the hotspot codon Q61 (Q61R/K), and all but one co-occurred with PIK3CA or PIK3R1 mutations. In addition, HRAS Q61 hotspot mutations were significantly associated with necrosis (p=0.01) and high mitotic rates (p=0.03). CDKN2A homozygous deletions were also detected only in ER-negative AMEs (19%) and found to be significantly associated with progression to carcinoma (p=0.001). Forced expression of HRAS Q61R in MCF10A and MCF12A cells resulted in i) increased proliferation and transformation, ii) an irregular growth pattern in 3D organotypic cell cultures, iii) partial loss of the epithelial phenotype, and iv) acquisition of myoepithelial differentiation, which was more overt in PIK3CA-mutant MCF10A cells. HRAS Q61Rinduced hyperactivation of the PI3K pathway, but both PI3K and MAPK pathways likely contributed to the RAS-mediated proliferation, which was completely arrested by combined AKT and MEK inhibition.
Conclusion: AMEs are phenotypically and genetically heterogeneous. Whilst pathogenic mutations in PI3K pathway-related genes occur across the spectrum of lesions, HRAS Q61 hotspot mutations are restricted to ER-negative AMEs. Our genomic and functional analyses indicate that HRAS Q61 mutations are driver events in the pathogenesis of ER-negative AMEs and, in conjunction with mutant PIK3CA, may lead to the acquisition of myoepithelial differentiation in breast epithelial cells.
Citation Format: Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen H-C, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Lozada J, Macedo GS, Muenst S, Terracciano LM, Jungbluth A, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha E, Chandarlapatty S, Weigelt B, Reis-Filho JS. Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD4-13.
Collapse
Affiliation(s)
- FC Geyer
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - A Li
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - AD Papanastasiou
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - A Smith
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - P Selenica
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - KA Burke
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - M Edelweiss
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - H-C Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - S Piscuoglio
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - AM Schultheis
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - LG Martelotto
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - F Pareja
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - R Kumar
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - A Brandes
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - J Lozada
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - GS Macedo
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - S Muenst
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - LM Terracciano
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - A Jungbluth
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - MP Foschini
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - HY Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - E Brogi
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - J Palazzo
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - BP Rubin
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - CKY Ng
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - Z Varga
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - IO Ellis
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - E Rakha
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - S Chandarlapatty
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Basel, Basel, Switzerland; Bellaria Hospital, University of Bologna, Bologna, Italy; Thomas Jefferson University Hospital, Philadelphia, PA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; University of Nottingham, Nottingham, United Kingdom
| |
Collapse
|
10
|
Wen HY, Krystel-¬Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler M, Norton L, Morrow M, Hudis C, Brogi E. Abstract P1-09-14: Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The 21-gene recurrence score (RS) estimates the likelihood of distant recurrence and the benefit from chemotherapy in patients with early-stage node-negative, estrogen receptor (ER)-positive, HER2-negative breast carcinoma. The use of the assay resulted in a substantial reduction in adjuvant chemotherapy usage. In this study, we reviewed the outcome of patients with node-negative, ER+/HER2- breast cancer and low recurrence score treated at our center to further verify the prognostic value of the assay.
Design: We identified breast cancer patients treated at our center between 09/2008 and 08/2013 with ER-positive, HER2-negative breast cancer and known RS. We reviewed clinicopathological characteristics, RS, treatment and outcome data. The Institutional Review Board approved the study.
Results: We identified 1406 consecutive patients with early stage node negative ER+/HER2- breast cancer and low RS [RS 0-10: 510 (36%), RS 11-17: 896 (64%)] in the study period. The median age at breast cancer diagnosis was 56 years (range 22-90). Sixty-three (4%) patients were <40 years old at breast cancer diagnosis. A total of 1362 (97%) patients received endocrine therapy, and 170 (12%) received chemotherapy. The median follow up time was 46 months (range 1-85). Six (0.4%) of the 1406 patients developed biopsy proven distant metastases within 5 years of breast cancer diagnosis, 5 of which were in the RS 11-17 group (Table 1). Three of the 5 patients with RS 11-17 and distant metastases were younger than 40 years old at breast cancer diagnosis. In the RS 11-17 group, the absolute incidence of distant metastases among patients with breast cancer diagnosed at age younger than 40 years old is 7.1% (3/42), whereas the absolute incidence of distant metastases among patients ≥40 years is 0.2% (2/854).
Conclusion: Our results suggest that young age (<40 years old) might be a negative prognostic factor even in patients with low RS. Analysis of data from other studies is necessary to further validate this observation.
Table 1. Clinicopathologic characteristics of the 6 patients with ER-positive, HER2-negative, node-negative breast carcinoma of recurrence score <18 who developed distant metastasisPatients#1#2#3#4#5#6Age at diagnosis (years)505437713839Family history of breast/ ovarian cancerNoYesNoNoNoYesPersonal history of breast carcinomaNoIpsilateral DCISNoIpsilateral DCISNoNoTumor typeILCIDCIDCIDCIDCIDCTumor size (cm)2.11.32.72.31.62.1Tumor Grade222223LVINoNoNoNoYesNoER (%)909595959595PR (%)30585757595Oncotype DX RS51212131417SurgeryBTMTMBTMBCSBCSBTMRadiationNoNoNoYesYesNoEndocrine therapyYesYesYesYesNoYesChemoNoNoCMFNoNoNoTime interval to metastasis (months)584125204812Site of metastasisBoneMultipleLungMultipleMultipleBoneFollow-up (months)725359647142SurvivalAWDAWDAWDDODAWDAWDAbbreviations: RS, recurrence score; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; BTM, bilateral total mastectomy; TM, total mastectomy; BCS, breast conserving surgery; CMF, cyclofosphamide, metotrexate and 5-fluorouracil. AWD, alive with disease; DOD, died of disease.
Citation Format: Wen HY, Krystel-¬Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler M, Norton L, Morrow M, Hudis C, Brogi E. Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-14.
Collapse
Affiliation(s)
- HY Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - M Krystel-¬Whittemore
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - S Patil
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - F Pareja
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - ZL Bowser
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - M Dickler
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - M Morrow
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - C Hudis
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| | - E Brogi
- Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
11
|
Dong LQ, Huang SH, Wen HY, Feng Y, Duan XX. [Study on the excitation mechanism of upconversion red emission from Er3+ under square wave excitation]. Guang Pu Xue Yu Guang Pu Fen Xi 2010; 30:883-886. [PMID: 20545123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The rise and decay curves of Er3+ 4F9/2 upconversion emission in oxyfluoride tellurite glass were measured under the excitation at 808 nm from a laser diode driven by square waves. The lifetime of the intermediate state could be determined via rise times. Then the accumulation process of the 4F9/2 population was confirmed. The excitation mechanism of up-conversion red emission under 808 nm excitation was confirmed by the rate equations and analyzing the relationship between the time constants of the rise and decay processes and the intermediate state. Square wave excited upconversion emission may also be used for measuring lifetimes of infrared energy levels with a conventional photomultiplier tube.
Collapse
Affiliation(s)
- Li-Qiang Dong
- Key Laboratory of Luminescence and Optical Information (Ministry of Education), Institute of Optoelectronic Technology, Beijing Jiaotong University, Beijing 100044, China.
| | | | | | | | | |
Collapse
|
12
|
Schaubach BM, Wen HY, Kellems RE. Regulation of murine Ada gene expression in the placenta by transcription factor RUNX1. Placenta 2006; 27:269-77. [PMID: 16338472 DOI: 10.1016/j.placenta.2005.03.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2004] [Revised: 03/02/2005] [Accepted: 03/03/2005] [Indexed: 10/25/2022]
Abstract
The formation of the trophoblast cell lineage of the placenta is one of the first developmental events to occur in mammalian embryogenesis. To understand the mechanisms of gene regulation in the trophoblast cell lineage we have used the murine adenosine deaminase gene (Ada) as a model. Ada is highly expressed in trophoblast cells of the placenta and is critical for embryo development. A 770bp fragment of the mouse Ada 5' flanking region is capable of directing trophoblast cell-specific expression in a transgenic model system. Earlier studies identified several critical portions of this fragment, including three footprinting regions that are necessary for correct gene expression in the placenta. Using electromobility shift assays (EMSA), we identified a 5bp sequence within footprint 3 that computer databases predicted bound to the transcription factor RUNX1 (also known as acute myeloid leukemia 1). This prediction was confirmed by supershift analysis using antibodies specific for RUNX1. The functional importance of this binding was demonstrated by both transient transfections and transgenic approaches. A significant reduction in expression of the reporter gene in the placenta was seen when the 5bp RUNX1 binding site was mutated. The findings reported here indicate that the RUNX1 transcription factor plays a significant role in regulating Ada gene expression in the trophoblast cell lineage.
Collapse
Affiliation(s)
- B M Schaubach
- University of Texas at Houston, Biochemistry and Molecular Biology, 6431 Fannin, Houston, TX 77030, USA
| | | | | |
Collapse
|
13
|
Abstract
The proliferation and differentiation of trophoblast cells is under the control of a variety of hormones and growth factors and is influenced by nutrient availability. The intracellular signaling pathways acting downstream of these mitogenic factors and nutrients to regulate trophoblast proliferation and placental development are poorly understood. Immortalized human trophoblast cells were used (HTR-8/SVneo) to investigate trophoblast proliferation in response to angiopoietin-2 (Ang-2), a major angiogenic factor and glucose (a major nutrient). Trophoblast cell proliferation was induced through activation of the phosphatidylinositol-3 (PI-3) kinase and the mammalian target of rapamycin (mTOR) signaling pathways, following Tie-2 receptor activation. Glucose also stimulated trophoblast cell proliferation through mTOR signaling. Ang-2 activated mTOR via PI-3 kinase-dependent signaling; whereas glucose-mediated mTOR activation was PI-3 kinase-independent and involved a novel nutrient sensor, glutamine fructose-6-phosphate amidotransferase (GFAT). Metabolites of the GFAT reaction acted upstream of mTOR and functioned as a nutrient sensor to regulate trophoblast cell proliferation in response to glucose. Overall, the results show that growth factor and nutrient signaling converge at tuberin, an upstream regulator of mTOR and that mTOR functions as an important placental growth signaling sensor. These results are the first to link mTOR with GFAT metabolites as nutrient sensors for trophoblast cell proliferation.
Collapse
Affiliation(s)
- H Y Wen
- Department of Biochemistry and Molecular Biology, University of Texas, Houston Medical School, Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
14
|
Cazaban S, Maïza D, Coffin O, Radoux JM, Mai C, Wen HY. Surgical Treatment of Recurrent Carotid Artery Stenosis and Carotid Artery Stenosis after Neck Irradiation: Evaluation of Operative Risk. Ann Vasc Surg 2003; 17:393-400. [PMID: 14670017 DOI: 10.1007/s10016-003-0020-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Surgical treatment of recurrent carotid artery stenosis after endarterectomy and carotid artery stenosis after neck irradiation purportedly has a higher complication rate than primary carotid endarterectomy (CEA). Accordingly, carotid angioplasty has been proposed as a safer alternative. The purpose of this study was to evaluate operative risks on the basis of our experience with these lesions. A series of 679 carotid revascularizations (CRV) performed over a period of 9 years was retrospectively reviewed. Immediate outcome and operative technique was analyzed in three groups: group 1 included 549 "routine" CRV, group 2 included 8 CRV for recurrent stenosis after CEA, and group 3 consisted of 11 CRV for stenosis after neck irradiation. No difference in revascularization techniques was found between groups 1 and 2. In contrast there were fewer CEA and resection-anastomosis procedures in group 2 than in group 1 (62.5% vs. 98.2%; p < 0.0006) and more bypass procedures (37.5% vs. 1.8%; p = 0.0015). The cumulative neurological morbidity/mortality rate (CMMR) was 0% in groups 2 and 3 as compared to 4.4% in group 1. In comparison with group 1, early and permanent neurological morbidity rates were significantly higher in both group 2 (2.2% vs. 25.0%; p = 0.015 and 0.2% vs. 12.5%; p = 0.028, respectively) and group 3 (2.2% vs. 18.2%; p = 0.028 and 0.2% vs. 9.1%; p = 0.039, respectively). Surgical treatment of recurrent stenosis after CEA and stenosis after neck irradiation is not associated with a higher CMMR. The only potentially valid justification for using percutaneous transluminal angioplasty in these patients would be a higher risk of cervical neurological morbidity.
Collapse
Affiliation(s)
- S Cazaban
- Service de Chirurgie Thoracique et Cardio-vasculaire, CHU Côte de Nacre, Caen, France
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
Adenylosuccinate synthetase 1 (ADSS1) functions as an important component in adenine nucleotide biosynthesis and is abundant in the heart. Here we report that the Adss1 gene is up-regulated in two in vivo rodent models of surgically induced cardiac hypertrophy. In addition, we examined an in vitro hypertrophy system of rat neonatal cardiomyocytes treated with angiotensin II to study Adss1 gene regulation. We show that this stimulus triggers a signaling cascade that results in the activation of the Adss1 gene. The induction of Adss1 gene expression was blocked by cyclosporin A in vitro, suggesting that calcineurin, a calmodulin activated phosphatase, is involved in this signaling pathway. Consistent with this view we provide evidence that the induction of Adss1 by angiotension II requires the presence of an NFAT binding site located 556 base pairs upstream of the Adss1 transcription start site. We propose that ADSS1 plays a role in the development of cardiac hypertrophy through its function in adenine nucleotide biosynthesis.
Collapse
Affiliation(s)
- H Y Wen
- Department of Biochemistry and Molecular Biology, University of Texas, Medical School at Houston, Suite 6.200, 6431 Fannin Street, Houston, Texas 77030, USA
| | | | | | | | | |
Collapse
|
16
|
Wen HY, Chou ML, Lin KL, Kao PF, Chen JF. Recurrence of pneumococcal meningitis due to primary spontaneous cerebrospinal fluid fistulas. Chang Gung Med J 2001; 24:724-8. [PMID: 11820653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
The authors report a case of pneumococcal meningitis which recurred 3 times in a Taiwanese boy due to spontaneous cerebrospinal fluid (CSF) fistulas. The first time occurred at the age of 2 years, and the second episode presented as meningoencephalomyelitis at the age of 6 years 10 months. Studies including serum levels of immunoglobulin and complements, brain magnetic resonance imaging, and coronal cranial computed tomography (CT) were negative for a specific etiology. The third episode of meningitis developed 2 months after the second episode. Repeated immunological studies and high-resolution CT of paranasal sinuses and temporal bones were negative. Technetium-99m diethylenetriamine pentaacetic acid (Tc-99m-DTPA) radionuclide cisternography revealed abnormal retention of radioactivity over the right mastoid area. Neurosurgery was undertaken to seal the dural tear and pack the petrosal fissure. Two years after surgery, he has had no further CSF leak age or meningitis. Tracing back the history, there was no head injury, cranial surgery, brain tumor, or hydrocephalus, which might have created CSF fistulas. Primary spontaneous CSF fistulas constitute the most reasonable diagnosis. In cases of recurrent bacterial meningitis, underlying anatomic defects should be carefully evaluated if there is no immune defect.
Collapse
Affiliation(s)
- H Y Wen
- Division of Pediatric Neurology, Chang Gung Children's Hospital, Taipei, ROC
| | | | | | | | | |
Collapse
|
17
|
Bai H, Wen HY. Performance of the annular denuder system with different arrangements for HNO3 and HNO2 measurements in Taiwan. J Air Waste Manag Assoc 2000; 50:125-130. [PMID: 10680373 DOI: 10.1080/10473289.2000.10463991] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Experiments on different annular denuder system (ADS) arrangements for sampling nitrous acid (HNO2) and nitric acid (HNO3) gases were conducted in this study to evaluate their sampling artifacts. The evaluation basis is the one that employed one sodium chloride denuder for sampling HNO3 gas and two sodium carbonate (Na2CO3) denuders for sampling HNO2 gas, which is a commonly employed ADS arrangement in many field applications in the United States. A field study was conducted in Hsinchu, Taiwan, and the results indicated that this ADS arrangement may yield over 80% relative errors for HNO3 gas. It also showed that the relative errors for HNO2 gas can be less than 10% as sampled with only one Na2CO3 denuder. This is attributed to the fact that the ambient HNO3 concentration measured in this study was relatively low while the HNO2 concentration was high, as compared to typical concentrations of these two gases measured in the United States. The sampling error of HNO3 gas may be due to high concentrations of N-containing interfering species present in Taiwan's atmosphere. Because the relative sampling errors of HNO3 and HNO2 gases depend mainly on their concentrations in the atmosphere as well as concentrations caused by interfering species, the risk for high error while measuring low HNO2 concentrations by only one Na2CO3 denuder is also possible. As a result, it is suggested that pretests are necessary to evaluate possible sources and degrees of sampling errors before field sampling of HNO2 and HNO3 gases. The sampling errors of these two gases can, therefore, be minimized with a better arrangement of the ADS.
Collapse
Affiliation(s)
- H Bai
- Institute of Environmental Engineering, National Chiao-Tung University, Hsinchu, Taiwan.
| | | |
Collapse
|
18
|
Wen HY, Davis RL, Shi B, Chen JJ, Chen L, Boylan M, Spallholz JE. Bioavailability of selenium from veal, chicken, beef, pork, lamb, flounder, tuna, selenomethionine, and sodium selenite assessed in selenium-deficient rats. Biol Trace Elem Res 1997; 58:43-53. [PMID: 9363319 DOI: 10.1007/bf02910665] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The bioavailability of selenium (Se) from veal, chicken, beef, pork, lamb, flounder, tuna, selenomethionine (SeMet), and sodium selenite was assessed in Se-deficient Fischer-344 rats. Se as veal, chicken, beef, pork, lamb, flounder, tuna, SeMet, and sodium selenite was added to torula yeast (TY) basal diets to comprise Se-inadequate (0.05 mg Se/kg) diets. Se as sodium selenite was added to a TY basal diet to comprise a Se-adequate (0.10 mg Se/kg), Se-control diet. The experimental diets were fed to weanling Fischer-344 rats that had been subjected to dietary Se depletion for 6 wk. After 9 wk of the dietary Se repletion, relative activity of liver glutathione peroxidase (GSHPx) from the different dietary groups compared with control rats (100%) was: flounder 106%, tuna 101%, pork 86%, sodium selenite 81%, SeMet 80%, beef 80%, chicken 77%, veal 77%, and lamb 58%. Se from flounder was the most efficient at restoring Se concentrations in the liver and skeletal muscle. Se from sodium selenite, SeMet, beef, veal, chicken, pork, lamb, and tuna was not dietarily sufficient to restore liver and muscle Se after 9 wk of recovery following a 6-wk period of Se depletion.
Collapse
Affiliation(s)
- H Y Wen
- Texas Tech University, Lubbock 79409, USA
| | | | | | | | | | | | | |
Collapse
|